Hardman & Co Research 2

Q&A on Arbuthnot Banking Group (ARBB) | 2023 results, strategic choices paying dividends

Q&A on H&T Group (HAT): 2023 results – strong core growth

Hardman & Co Research on Chesnara plc (CSN): Good 2023 results set platform for future progress

Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth

Q&A on NB Private Equity Partners (NBPE): Offsetting higher interest rates, leaving return targets unchanged

Q&A on Real Estate Credit Investments (RECI): Conservative accounting at play

Hardman & Co Research on NB Private Equity Partners (NBPE): Value creation in a higher-rate environment

Hardman & Co Research on City of London Investment Group (CLIG): First-half results going in the right direction

Hardman & Co Research on Real Estate Credit Investments (RECI): French and German exposures in perspective

Q&A on H&T Group (HAT): Long-term pawnbroking growth, short-term cost and retail pressure

Hardman & Co Research on City of London Investment Group (CLIG): Bounce back in FUM after strong quarter

Hardman & Co Research on H&T Group (HAT): Growing pawnbroking core will drive other services

Hardman & Co Q&A on ICG Enterprise Trust (ICGT): Analysing the risk and reward opportunity for investors

Hardman & Co Video | Surface Transforms (SCE) Open Offer and Q&A

Hardman & Co Research on Apax Global Alpha (APAX): “Hidden Gems” strategy: green shoots into live deals

Hardman & Co Video | The International Stock Exchange (TISE): Exposure to exchanges plus a private company initiative

Hardman & Co Research on Surface Transforms (SCE): Funding for growth: Open Offer

Hardman & Co Video | Chesnara (CSN) Presentation and Q&A with Management

Hardman & Co Research | Real Estate Credit Investments (RECI): Portfolio management to optimise risk/reward

Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team

Hardman & Co: Q&A on NB Private Equity Partners (NBPE): How NBPE benefits from value creation through growing companies

Hardman & Co Research : ICG Enterprise Trust (ICGT) – 1HFY’24: defensive growth/disciplined approach

Hardman & Co Research | Q&A on NB Private Equity Partners (NBPE): Continued growth reported in 1H’23 results

Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H’23

Hardman & Co Research | Q&A on NB Private Equity Partners (NBPE): PE co-investment niche to generate superior returns

CORRECTION Hardman & Co Video | Chesnara (CSN) Presentation and Q&A with Management

Hardman & Co Research | City of London Investment Group (CLIG): Positive markets offset by revenue margins

Hardman & Co Video | Surface Transforms (SCE) Presentation and Q&A with the Board

Hardman & Co Research: Volta Finance Limited (VTAS): An easy guide to the benefits of CLOs

Hardman Talks Video Event | Surface Transforms Management Presentation and Q&A